Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AAV-CNGB3 Gene Therapy for Achromatopsia
NCT03001310Phase 2Completed
- Sponsor
- MeiraGTx
- Start
- Jan 2017
- Primary completion
- Oct 2019
- Modality
- Gene Editing, Gene Silencing, AAV Vectors
- Countries
- 2
01
Overview
Phase 2, open-label trial of entacingene turiparvovec in achromatopsia (ACHM) (3 arms), sponsored by MeiraGTx. Primary endpoint: Number of Participants Meeting the Primary Outcome Defined as Any Adverse Events Occurring During the 6 Weeks Following Administration. Started Jan 2017; status: completed.
02
Drugs
entacingene turiparvovec
03
Conditions
achromatopsia (ACHM)
Beyond the preview
Go deeper on NCT03001310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03001310.